Today’s article highlights “a low-risk, high-quality small biotech with high growth potential.” More specifically, this “is a revolutionary biotech company that uses tissue engineering to treat/repair sports-related injuries and severe burns” – and while it was negatively impacted this year by the canceling and delaying of elective surgeries due to COVID-19, the author outlines why rapid growth should return in 2021. For more, CLICK HERE.
